Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
Angewandte Chemie (International Ed. in English)|February 3, 2021
Structural Revision of Natural Cyclic Depsipeptide MA026 Established by Total Synthesis and Biosynthetic Gene Cluster AnalysisChihiro Uchiyama, Akane Fukuda, Minagi Mukaiyama, et al.Bioorganic & Medicinal Chemistry|November 5, 2019
Pyrenocine A induces monopolar spindle formation and suppresses proliferation of cancer cellsYusuke Myobatake, Shinji Kamisuki, Senko Tsukuda, et al.Journal of Medicinal Chemistry|June 23, 2023
X-Ray Conformation and Structure-Activity Relationships of MA026, a Reversible Tight Junction OpenerMinagi Mukaiyama, Chihiro Uchiyama, Akane Fukuda, et al.Journal of Natural Products|September 30, 2025
Ufisonitriles A and B, Antimalarial Isonitriles with Mitochondrial Function Inhibitory Activity Produced by Amycolatopsis sp. OK19-0009Emi Arakawa, Yoshihiro Watanabe, Hayama Tsutsumi, et al.NPJ Systems Biology and Applications|January 28, 2022
High-throughput platform for yeast morphological profiling predicts the targets of bioactive compoundsShinsuke Ohnuki, Itsuki Ogawa, Kaori Itto-Nakama, et al.Journal of Medicinal Chemistry|December 22, 2011
Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structureYuri Yamazaki, Koji Tanaka, Benjamin Nicholson, et al.Bioscience, Biotechnology, and Biochemistry|July 9, 2024
Discovery of an antimalarial compound, burnettiene A, with a multidrug-sensitive Saccharomyces cerevisiae screening system based on mitochondrial function inhibitory activityAoi Kimishima, Atsuka Nishitomi, Iori Tsuruoka, et al.Plos One|February 7, 2023
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinomaKazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.Journal of Gastroenterology|April 21, 2026
On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 yearsTetsuya Hosaka, Hayato Hikita, Yuki Tahata, et al.Plos One|January 2, 2024
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational studyMachiko Kai, Hayato Hikita, Maesaka Kazuki, et al.Pageof 11